The marker in question is called DOPA decarboxylase (DCC). In the current study, DCC was found to be elevated in individuals with Parkinson’s disease as well as in people with other diseases that result in dopamine deficiency in the brain. However, the marker was normal in other brain diseases such as Alzheimer’s disease. The researchers even noticed that DCC was elevated in individuals with Parkinson’s many years before they developed any symptoms.
Zyme Communications expands UK head office with new facilities at Cambridge Innovation Park
Zyme Communications Ltd., life science specialist PR and marketing agency, today announced the expansion of its UK headquarters with a move to larger office premises
April 18, 2024